PDS Biotechnology Corp Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
PDS Biotechnology Corp (PDSB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-30
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-09-30 was 0.00%.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-06-30 was 0.00%.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-09-30 was 0.00%.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-30 | ||||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-14 | 0.00% 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-13 | 0.00% 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-14 | 0.00% 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-13 | 0.00% 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-14 | 0.00% 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-14 | 0.00% 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-28 | ||||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-14 | 0.00% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-08 | 0.00% 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-10 | 0.00% 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2021-08-12 | 0.00% 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-18 | ||||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-13 | 0.00% 10-Q · filed 2020-11-13 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-13 | 0.00% 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-13 | ||||
| 2019-03-13 | 0.00% 10-K · filed 2021-03-18 | ||||
| 2018-12-31 | 0.00% 10-K · filed 2019-02-21 | ||||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-07 | 0.00% 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-01 | 0.00% 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-14 | ||||
| 2017-12-31 | 0.00% 10-K · filed 2019-02-21 | ||||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-01 | 0.00% 10-Q · filed 2018-11-01 | |||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-01 | 0.00% 10-Q · filed 2018-08-01 | |||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-01 | ||||
| 2016-12-31 | 0.00% 10-K · filed 2018-03-01 | ||||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-01 | 0.00% 10-Q · filed 2017-11-01 | |||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-01 | 0.00% 10-Q · filed 2017-08-01 | |||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-03 | ||||
| 2015-12-31 | 0.00% 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-01 | 0.00% 10-Q · filed 2016-11-01 | |||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-03 | 0.00% 10-Q · filed 2016-08-03 | |||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-03 | ||||
| 2014-12-31 | 0.00% 10-K · filed 2017-03-02 | ||||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-06 | 0.00% 10-Q · filed 2015-11-06 | |||
| 2013-12-31 | 0.00% 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |